Loading
Life sciences · Journal article
Scientific Reports · October 21, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Precise control of oncogene expression is crucial for advancing tumor biology research and therapeutic testing. To address the limitations of current systems, we developed a novel, tightly regulated, genome-integrable inducible expression platform based on an optimized cumate gene-switch system. By engineering a KRAB-fused, NLS-enhanced CymR repressor (CSwitch-Silencer), a CpG-free hybrid promoter, and a PiggyBac-based integration strategy, insulated by matrix attachment regions, we achieved robust, reversible, and dose-dependent transgene expression with basal activity below detection. With the receptor tyrosine kinase cMET as a model, we generated CRISPR–Cas9-derived cMET -deficient A549 cells and established inducible lines expressing wild-type and clinically relevant variants, including exon 14 skipping and H1094Y. The system enabled precise tuning of expression levels and faithful recapitulation of downstream signaling and phenotypic responses. Pharmacological profiling revealed variant-specific sensitivities to clinically relevant MET inhibitors, with the H1094Y mutation exhibiting increased sensitivity to the type II inhibitor cabozantinib, while exon 14 skipping conferred reduced sensitivity. These effects were consistent across biochemical and functional assays, including receptor activation and cell migration. Collectively, this platform provides a versatile and scalable approach for modeling oncogene function and drug response in a controlled genetic context. Its tight regulation, modular design, and stable genomic integration make it broadly applicable for functional characterization of cancer-associated variants and for preclinical evaluation of targeted therapies.